GLP-1a: Going beyond Traditional Use
US$ 23.38
do glp-1 agonists have cardiovascular benefit Bridging the gap between GLP1-receptor and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology SGLTi and GLP-1 in HF
Description
Obesity and insulin resistance sustain elevated circulating concentrations of pro-inflammatory cytokines including Tumour Necrosis Factor-alpha (TNF-), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) molecules that promote DNA damage, tumour angiogenesis, and immune evasion
The introduction of highly efficacious and generally safe medications for obesity treatment, such as GLP-1RAs, has disrupted this framework, reframing obesity as a medical issue that can be treated pharmacologically
TimmersLHenriquesJPde KleijnDPDevriesJHKempermanHSteendijkPet alExenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
The second cause for concern stemming from an increased use is patients access
The anti-apoptotic gene bcl- 2 is a promoter of transcription in the nucleus by a complex between CREB and TORC2
Diabetologia 2004
